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Abstract: The aim of this article was to study the trans-epithelial absorption to reach the blood
and to target the brain by axonal transport using nasal formulations with nanonized meloxicam
(nano MEL spray) and its salt form known as meloxicam potassium monohydrate (MELP spray).
The physicochemical properties and the mucoadhesivity of nasal formulations were controlled.
In vitro and in vivo studies were carried out. These forms were first investigated in “nose-to-brain”
relation. It was found that the in vitro study and in vivo study did not show any significant correlation.
In vitro experiments demonstrated faster dissolution rate and higher diffusion of MELP from the
spray compared with the nano MEL spray. The administration of the nano MEL spray resulted in
faster absorption and constant plasma concentration of the drug after five minutes of administration
as compared to MELP. The axonal transport of the drug was justified. MEL appeared in the brain
tissues after the first five minutes of administration in the case of both spray forms, but its amount
was too small in comparison with the total plasma concentration. The application of the nano MEL
spray resulted in the same AUC in the brain as the intravenous injection. The “nose-to-blood”
results predicted the nasal applicability of MEL and MELP in pain management. The “nose-to-brain”
pathway requires further study.
Keywords: nanosized meloxicam; meloxicam potassium monohydrate; intranasal formulation;
dissolution rate; in vitro diffusion; plasma drug-content; absolute bioavailability for brain
1. Introduction
Besides the local effect, intranasal (IN) administration is a potential way of delivering drugs
through the trans-epithelial absorption into the systemic circulation (“nose-to-blood” transport) [1,2],
which results in systemic effect or, by absorption through the blood-brain-barrier (BBB), central
nervous systemic (CNS) effect [3]. Some active pharmaceutical ingredients (APIs) can be delivered
directly from the nasal cavity into the CNS through the axonal transport (“nose-to-brain”) [4–6]. A new
approach is to target the brain with different API-containing drug delivery systems (DDSs) [7] in cancer
(docetaxel) [8] and migraine therapy (zolmitriptan) [9] or in CNS diseases. For effective therapeutic
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management of schizophrenia, risperidone liposomes and paliperidone microemulsion were developed
for “nose-to-brain” targeting [10,11]. Nanoparticle encapsulated tarenflurbil, piperine-loaded chitosan
nanoparticles, and polyethylenimine conjugated peptide containing nose drops were formulated
to deliver treatment for Alzheimer’s disease [12–14]. Levodopa-containing solution and powder
including lactoferrin-modified rotigotine nanoparticles were administered in order to increase their
therapeutic efficacy for Parkinson’s disease [15,16].
Non-steroidal anti-inflammatory drugs (NSAIDs) are mostly suggested for acute pain therapy or
they are co-administered as adjuvants to enhance analgesia [17,18]. The rapid absorption of NSAIDs
through the nasal mucosa into the systemic circulation and directly through the axonal route to
the brain tissue can have a role in reducing pain and fever by inhibiting cyclooxygenase (COX-2)
activity [19]. Few data are available on the applicability of NSAIDs in a nasal formulation. Ketorolac
tromethamine-containing solution has been administered intranasally [20] and dissolved meloxicam
(MEL)-containing nasal formulation was patented by Castile et al. [21]. In both cases, the main
purpose was to reach the systemic circulation. MEL is a poorly water-soluble NSAID, which can
be administered intranasally in order to attain an analgesic effect without a toxic effect on the nasal
epithelium [22]. The solubility, the rate of dissolution, and the permeability of drugs are of great
importance [23]. Our research team has experience in the field of application of different techniques
for the preparation of MEL in order to produce nasal formulations with improved bioavailability.
In vitro and in vivo investigations of micro- and nanonized MEL-containing IN formulations, prepared
with combined wet milling, were performed, which showed better diffusion and a higher plasma
AUC of the nanosized MEL-containing formulation compared to the raw or micronized drug [24].
The bioavailability of the salt form of MEL (meloxicam potassium monohydrate—MELP) [25,26] was
also investigated [27]. MELP revealed a higher permeability through the synthetic membrane and a
higher plasma concentration compared to the MEL-containing formulation. In every case, IN viscous
formulations were prepared by adding sodium hyaluronate (HA) as a mucoadhesive agent [28], which
was important from the aspect of a longer residence time. In case of these studies, the “nose-to-blood”
route of drugs was investigated and the direct axonal route was not examined.
According to our previous results, the aim was the comparison study of the trans-epithelial
absorption of MEL and MELP into the systemic circulation and brain by axonal transport. Nasal sprays
were formulated containing nanonized MEL (nano MEL spray) and its salt form (MELP spray) by using
HA as a mucoadhesive agent. The features of salt form and of the nanonized MEL enable the rapid
dissolution of both materials. The formulations were controlled by physicochemical investigation and
the mucoadhesivity test after the in vitro and in vivo studies were carried out.
2. Results and Discussion
2.1. PSD and Morphology
The average MEL particle size measured by laser diffraction decreased from approximately 35 µm
to 0.135 µm during the 50 min milling time. The SSA of MEL rose 135-fold as a result of the nanonization.
The coating effect of poly(vinyl alcohol) (PVA) prevented aggregation and the stability of the system
was, therefore, improved. The particle size distribution of MELP, with D50 = 21.38 µm, fell into the
range of the particle size distribution requirements of intranasally administered formulations (from 5
to 40 µm) [29].
The SEM images (Figure 1) provided an indication of the morphology of the particles.
The nanonized MEL crystals exhibited a regular shape and a smooth surface. The treatment accounted
for the smooth surfaces of the particles. The crystals of MELP were misaligned and, therefore, had a
different habit (form, surface, and size).
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Figure 1. SEM images of nanonized MEL (A) and MELP (B).
2.2. Viscosity and Mucoadhesion
The mean viscosity value determined at 1001/s was 62.50 ± 2.40 mPas in the case of nano MEL
spray and 71.25 ± 2.19 mPas of MELP spray. According to these results, it can be concluded that the
prepared liquid formulations with low viscosity values were suitable to form intranasal sprays.
For the rheological determination of mucoadhesivity, the samples were mixed with mucin (final
mucin concentration 5%) and the synergism parameter (bioadhesive viscosity component, ηb) was
calculated. The mucoadhesivity of the HA spray in the phosphate buffer (at pH 5.60), without PVA,
the PVA solution without HA, the blank, and the sprays were investigated.
The synergism parameter indicated the mucoadhesivity of the samples with an interaction
between the HA and the mucin (see Table 1). PVA did not reveal mucoadhesive features despite
the mucin-HA interactions. Accordingly, the mucoadhesivity of blank decreased compared to the
HA solution without PVA. The highest synergism was observed between the nasal spray containing
nanonized MEL and the mucin. The mucoadhesivity increased 4-fold compared to the MEL-free blank
and, therefore, the longest residence time could be reached. This could be explained, on the one hand,
by the particle size of MEL. The nano-sized particles have increased adhesiveness to surfaces [30].
On the other hand, nano-sized MEL is in size of polymeric molecules such as HA, PVA and mucin
chains, which can result in a well-structured complex and better interaction among the components
and thus it shows more remarkable mucoadhesivity [24]. Adding the ionic drug (MELP) decreased the
synergism, which can be explained by the interaction of the salt and the HA polymers [27,31].
Table 1. Calculated synergism parameters at shear rate of 1001/s of spray forms.
HA Spray PVA Solution Blank (HA + PVA) Nano MEL Spray MELP Spray
Synergism
parameters (mPa*s) 165 ± 30 −10 ± 1 90 ± 30 355 ± 25 59.4 ± 20
2.3. Dissolution Testing
MELP showed significantly higher solubility in water (due to alkali-hydrolyzation) than MEL.
However, at the pH of the nasal mucosa (pH 5.60) there were no differences, the solubility was
0.017 mg/mL in case of both materials. The in vitro dissolution test was achieved at a pH of 5.60, which
simulated the conditions of the nasal cavity. Despite the same equilibrium solubilities, the difference
in their rates of dissolution was perceptible. Quicker dissolution of the salt form was determined.
Figure 2 shows the amount of MELP dissolved during 1 h (0.015 mg/mL) in accordance with its
equilibrium solubility at the same pH. Nano MEL spray had an initial dissolution burst due to the
larger surface of particles (44.8 m2/g). However, in this case, a lower amount of drug dissolved when
compared with MELP spray.
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Figure 2. Extent of dissolution of MEL and MELP from nasal formulations at pH 5.60.
2.4. In Vitro Diffusion
Application of Side-Bi-SideTM model provided the continuous stirring of the donor phase because
of the homogeneous distribution of the suspended drugs. Figure 3 shows that, in spite of the same
solubilities of MEL and MELP at pH 5.60, the drug from MELP spray permeated at a higher rate of pH
5.60 through the membrane than MEL from nano MEL spray, which demonstrated a faster diffusion
and a higher drug concentration. This could be explained by the formation of a well-structured
structure between nanonized MEL particles with PVA and HA, which resulted in a low dissolution
rate of the drug.
Figure 3. In vitro permeability of the sprays through a synthetic membrane.
2.5. In Vivo Studies
Nanonized MEL and MELP containing IN spray forms were investigated through in vivo studies.
Changes of drug concentration in the blood plasma as a function of time after the nasal administration
of the sprays and, as a control, of the IV injection are shown in Figure 4. The plasma concentration
of MEL was significantly higher in the IV group in the first 60 min. The highest measured plasma
concentrations (10,554 ± 0.147 nM) were reached five minutes after the initiation of the IV injection.
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There were significant differences between the plasma concentrations in the case of spray forms only
in the first five minutes after application. The plasma concentration increased slowly during the first
approximately 60 min in the case of the MELP-containing form in contrast with nano MEL spray where
peak plasma concentration was reached in the first five minutes after administration. The nanosized
MEL is in the size of polymeric molecules, such as HA, PVA, and mucin chains, which can result in
a well-structured complex and better interaction among the components. Therefore, it shows more
remarkable mucoadhesivity and a longer residence time [24]. In both cases, a controlled release of
drugs was observed one hour after the administration of IN spray formulations.
Figure 4. Plasma drug concentration vs. time profiles in rats after IV MEL and intranasal administration
of nano MEL and MELP sprays.
The AUC is proportional to the amount of drug absorbed during the investigated time
interval. Plasma AUC values of IN sprays were almost the same (nano MEL spray: 492,007.3
± 95,176.23 min·ng/mL; MELP spray: 538,393 ± 105,892.4 min·ng/mL) and significantly lower
(**; p ≤ 0.01) than in the case of IV administration (1,351,000 ± 82,000 min·ng/mL) (see Figure 5).
This phenomenon could be explained with the 100% bioavailability of drugs after IV administration,
which is always lower in case of extravascular administration routes.
Figure 5. AUC values in the blood plasma of IV MEL and sprays contain nano MEL and MELP.
The concentration values of MEL in the brain samples vs. time profiles in case of IV and IN
administration are shown in Figure 6. The application of the nano MEL containing sample resulted in a
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higher drug concentration (0.88 nM) in the brain tissues compared to the IV MEL and MELP. The axonal
(direct “nose-to-brain”) transport of the drug was presumable by both IN spray formulations because
the drug appeared in the brain in the first five minutes after administration. This could not be reached
by the absorption from the nasal mucosa to the systemic circulation, which passed through BBB.
One hour later, the drug-level in the brain was increased, which could already be explained with the
drug absorption through the BBB from the blood plasma. The swallowing of the nasal preparation was
possibly not significant since the tmax value was much higher (110.6 min) after the oral administration
of dissolved MEL-containing viscous formulation [22].
Figure 6. Drug concentration in the brain vs. time profiles in rats after IV MEL and intranasal
administration of nano MEL and MELP sprays.
The calculated cerebral AUC values of the formulations did not show significant differences
(see Figure 7). Administration of nano MEL particles resulted in the same AUC value (35.72 ±
8.792 min·ng/mL) as the IV administration (35.72 ± 2.355 min·ng/mL). Due to the quick dissolution
of nanoparticles, a high amount of MEL could reach the brain directly by axonal transport, which
resulted in the same AUC as compared with that of the IV injection where MEL should be absorbed
through the BBB to target the brain.
Figure 7. AUC values in the brain tissues of IV MEL and sprays contain nano MEL and MELP.
To determine the utilization of the drug in the brain tissue, the absolute bioavailability was
calculated where the brain AUC—resulted by IV MEL—was considered 100% (see Table 2). In case of
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nano MEL spray, the absolute bioavailability of MEL was 100% while, in case of MELP spray, it was
only about 60%. These results were added from the double transport in contrast to the IV MEL.
The cerebral drug targeting efficiency index (% DTE) reflects the relative accumulation of the
drug in the brain following IN administration as compared to systemic (IV) administration. In case of
IN formulations, % DTE data were above 100% in both cases. Therefore, drug delivery to the brain
following IN administration was more efficient when compared to systemic administration. This could
be explained with both axonal and epithelial routes of drugs compared to IV administration where the
APIs could reach the brain tissues only through the BBB.
Table 2. Calculated parameters of spray forms apply IV administration as a benchmark.
abs. BA for Brain (%) AUCbrain/AUCblood DTE (%)
IV MEL 100 2.644 × 10−5 100
nano MEL spray 100 7.26 × 10−5 274.58
MELP spray 59 3.93 × 10−5 148.64
3. Experimental Set-Up
3.1. Materials
MEL (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-benzothiazine-3-carboxamide-1,1-dioxide)
as a water-insoluble (0.040 mg/mL at 37 ◦C) agent and MELP (4-hydroxy-2-methyl-N-(5-methyl-
2-thiazolyl)-2H-benzothiazine-3-carboxamide-1,1-dioxide potassium monohydrate) as a water-soluble
(13.10 mg/mL at 37 ◦C) drug were obtained from EGIS Ltd. (Budapest, Hungary). Piroxicam, the internal
standard for the HPLC method, was purchased from the Alfa Aeasar Co. (Alfa Aeasar GmbH & Co.
KG, Karlsruhe, Germany). The grinding additive, PVA 4-98 (Mw ~27,000), was procured from Sigma
Aldrich (Sigma Aldrich Co. LLC, St. Louis, MO, USA). HA (Mw = 1400 kDa) was obtained as a gift
from Gedeon Richter Plc. (Budapest, Hungary). Mucin (porcine gastric mucin type II) was obtained
from Sigma Aldrich (Sigma Aldrich Co. LLC, St. Louis, MO, USA).
3.2. Methods
3.2.1. Sample Preparation
The content of intranasal spray forms are presented in Table 3. For the preparation of nano
MEL spray, combined wet milling techniques (a combination of planetary ball and pearl milling) was
applied to prepare the pre-dispersion. During milling, PVA was used as a coating polymer, which
promoted the separation of particles from each other. 0.5 g PVA was dissolved in 17.5 mL phosphate
buffer (PBS) (at a pH of 5.60, the pH of the nasal mucosa) to prepare a dispersant medium in which
2.0 g of MEL was suspended. The suspension was wet-milled in the planetary ball mill (Retsch PM
100) (Retsch GmbH, Haan, Germany) for 50 min using zirconium dioxide beads, which were 0.3 mm
in diameter in order to reach the nano-range. The milling medium for this study was zirconium
dioxide beads. The IN formulation (nano MEL spray) was prepared directly from the pre-dispersion
by diluting with phosphate buffer (pH 5.60) in order to reach 2 mg/mL concentration of MEL and
0.15 g HA as a natural anionic polysaccharide was added. Therefore, the final formulation contained
5 mg/mL HA.
MELP spray was developed with 2 mg/mL MELP and 5 mg/mL HA using phosphate buffer as
dispersant medium.
Intravenous (IV) injection (IV MEL) was prepared by the dilution of passable injection with
a concentration of 15 mg/1.5 mL (Meloxicam-Zentiva, Prague, Czech Republic) to reach the final
concentration (0.15 mg/mL). The components of injection were meglumine, poloxamer 188, glycine,
sodium hydroxide (for pH adjustment), sodium chloride, glycopherol, and water for injection.
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Table 3. Content of intranasal spray formulations.
MEL (mg) MELP (mg) PVA (mg) HA (mg) PBS of pH 5.60 (mL)
nano MEL spray 60.0 - 15.0 150.0 ad 30.0
MELP spray - 60.0 - 150.0 ad 30.0
3.2.2. Determination of Particle Size Distribution (PSD)
The volume-based PSD of MEL in the pre-dispersions was measured by using laser diffraction
(Mastersizer 2000) (Malvern Instruments Ltd., Worcestershire, UK) with the following parameters:
300RF lens, small volume dispersion unit (2500 rpm), refractive index for dispersed particles 1.720,
and refractive index for dispersion medium 1.330. A dynamic laser light scattering method was used to
determine the PSD. Water was applied as a dispersant and the obscuration was in the range of 11–16%
for all measurements. In all cases, the volume-weighted PSDs, D10, D50, and D90 (where, for example,
D50 is the maximum particle diameter below which 50% of the sample volume exists—also known as
the median particle size by volume) were determined and evaluated. The size analysis was repeated
three times. The specific surface area (SSA) was derived from the PSD data. The assumption was made
that all of the particles measured were spherical.
3.2.3. Image Analysis (SEM)
Pre-dispersions were dried in a vacuum dryer (Binder GmbH, Tuttlingen, Germany) at 40 ◦C
in order to obtain solid products for physical-chemical investigations. After drying, the shape and
surface characteristics of the samples were visualized by using SEM (Hitachi S4700, Hitachi Scientific
Ltd., Tokyo, Japan). The samples were coated with gold–palladium under an argon atmosphere by
using a gold sputter module in a high-vacuum evaporator and the samples were examined at 15 kV
and 10 µA. The air pressure was 1.3–13 MPa.
3.2.4. Rheology and Muco Adhesion
Rheological measurements were taken at 37 ◦C with a Physica MCR101 rheometer (Anton Paar
GmbH, Graz, Austria). A concentric cylindrical measuring device with a diameter of 10.835 mm was
used for the experiment. Viscosity curves were plotted to determine the viscosity of the samples. In the
shear rate interval from 0.1 to 1001/s, viscosity values were plotted.
To clarify the roles of nano MEL and MELP in muco-adhesion, samples were prepared with and
without mucin. The samples containing mucin were stirred for 3 h before the measurements (the
final mucin concentration was 5% w/w). The mucoadhesivity was determined on the basis of the
rheological synergism between the polymer and the mucin. The synergism parameter (bioadhesive
viscosity component, ηb) can be calculated from the following equation.
ηb = ηt − ηm − ηp
where ηt is the viscosity of the mucin and polymer-containing samples and ηm and ηp are the viscosities
of the mucin and nasal spray, respectively [32]. Three parallel measurements were used to determine
the viscosity values (ηt, ηm, and ηp) and the standard deviations.
3.2.5. In Vitro Dissolution Test
The paddle method (USP dissolution apparatus, type II; Pharma Test, Hainburg, Germany) was
used to examine the rates of dissolution of MEL- and MELP-containing intranasal spray forms and to
determine the drug release profile from the samples. The test was carried out under nasal conditions.
The medium was 100 mL PBS of pH 5.60 in which 3 mL of the samples were used. The paddle was
rotated at 50 rpm and the sampling was performed for 60 min. After filtration, the drug contents of the
aliquots were determined using spectrophotometry (Unicam UV/VIS Spectrophotometer) at 364 nm.
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3.2.6. In Vitro Diffusion Study
In vitro permeability studies were carried out on a modified horizontal Side-Bi-Side™ cell (Grown
Glass, New York, NY, USA), which modeled the conditions of nasal cavity. The validation of the in vitro
investigations were accomplished by comparing the results and measuring on the Side-Bi-Side™ cell
model with the results of the Franz-diffusion cell system (Hanson Microette Topical and Transdermal
Diffusion Cell System) (Hanson Research, Chatsworth, CA, USA) [24]. The intranasal spray was used
as a donor phase, which was prepared using phosphate buffer (PBS) of pH 5.60. This represents the pH
of the nasal cavity. The synthetic membrane (PALL Metricel membrane), impregnated with isopropyl
myristate, between the donor and acceptor compartments simulated the lipophilic nasal mucosa.
The pH (7.4) of the acceptor phase corresponded with the pH of the blood. The volumes of the donor
and the acceptor phase were the same (3.0 mL) and had a 0.69 cm2 diffusion area. The temperature
of the phases was 37 ◦C (Thermo Haake C10-P5, Sigma, Aldrich Co.) and the rotation rate of the
stir-bars was set to 100 rpm. Both phases were stirred with a magnetic stirrer, which simulated the
movements of the cilia and the blood circulation. Aliquots (2.0 mL) were taken from the acceptor phase
by pipette and were replaced with fresh receiving medium at 5, 10, 15, and 60 min of the measurement.
The amount of MEL or MELP diffused was determined spectrophotometrically (Unicam UV/VIS) at
364 nm. Each sample was measured three times.
3.2.7. In Vivo Studies
IN Administration, Blood Sample Collection, and Brain Removal
The IN formulations contained 2 mg/mL MEL and 5 mg/mL HA. A dose of 60 µg MEL per
animal was administered into the right nostril of 160–180 g male Sprague–Dawley rats (n = 4) via a
pipette. The administration was carried out under isoflurane short anesthesia. As a control, iv delivery
of the injection containing MEL in solution form (IV MEL) was given at a dose of 60 µg MEL per
animal to rats (n = 4). At predetermined time points (5, 10, 15, 30, 45, 60, 90, 120, 180, and 240 min) after
MEL dosing, the blood of the rats—under deep isoflurane anesthesia—was collected into heparinized
tubes by cardiac puncture. Then the animals were sacrificed by decapitation and brain tissues were
quickly removed, rinsed in ice-cold PBS, divided into left and right hemispheres, weighed, and stored
at −80 ◦C until assayed. The experiments were performed according to the EU Directive 2010/63/EU
for animal experiments and were approved by the Hungarian Ethical Committee for Animal Research
(permission number: IV/1247/2017).
Sample Preparation of Rat Plasma and Brain
Plasma samples were centrifuged at 1500 g for 10 min at 5 ◦C. Separated plasma samples were
stored at −80 ◦C until it was time for extraction and analysis. To a 90 µL of plasma sample, 10 µL 0.1%
aqueous formic acid and 300 µL acetonitrile containing piroxicam (internal standard at 12.5 ng/mL
concentration) were added and the mixture was spun for 60 s. The mixture was allowed to rest for
30 min at −20 ◦C to support protein precipitation. Supernatant was obtained by the centrifugation
of the mixture for 10 min at 10,000 g at 4 ◦C. 20 µL of clear supernatant was diluted by 380 µL 0.1%
aqueous formic acid and spun for 30 s. Finally, 5 µL was injected into the LC–MS/MS system for
analysis. The rat plasma calibration standards of MEL were prepared by moving the working standard
solutions (1–1000 ng/mL) into a pool of drug-free rat plasma. The procedure described above was
followed. Calibration standards consisted of 90 µL pooled plasma samples, 10 µL MEL standard
solution (in 0.1% aqueous formic acid), and 300 µL acetonitrile containing piroxicam (internal standard
at 12.5 ng/mL concentration). Solutions containing 6.25 ng/mL and 25 ng/mL MEL were used as QC
samples. 20 µL supernatant was taken out from both of the calibration standards and QC samples,
diluted with 380 µL 0.1% aqueous formic acid, and 5 µL was analyzed by LC–MS/MS.
The right hemispheres (0.8–1 g) of rats were homogenized in 5 mL 1% aqueous acetic acid using
an Ultra-Turrax homogenizer in an ice bath for 2 × 30 s interrupted by 30 s cooling. To 100 µL of brain
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homogenate, 20 µL 0.1% aqueous formic acid and 20 µL piroxicam internal standard (1.5625 ng/mL in
0.1% aqueous formic acid) were added and the mixture was vortex-mixed for 60 s. After centrifugation
for 10 min at 10,000 g at 4 ◦C, 40 µL supernatant was injected into the LC–MS/MS system for analysis.
Rat brain calibration standards of MEL were prepared by adding the working standard solutions
(1–1000 ng/mL) to a pool of drug-free rat brain. The procedure described above was followed.
Calibration standards consisted of 100 µL pooled brain samples, 20 µL MEL standard solution
(in 0.1% aqueous formic acid), and 20 µL piroxicam internal standard (1.5625 ng/mL in 0.1% aqueous
formic acid). Solutions containing 6.25 ng/mL and 25 ng/mL MEL were used as QC samples. After
centrifugation, 40 µL was analyzed by LC–MS/MS.
LC–MS/MS Analysis of MEL
The quantitative analysis of MEL was performed after chromatographically separating by
using mass spectrometry. An Agilent Liquid Chromatography System series 1100 including Micro
Vacuum Degasser, Capillary Pump, µ-WPS autosampler (Agilent Technologies, Waldbronn, Germany)
connected to a Q ExactiveTM Plus Orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose,
CA, USA) equipped with a heated ESI ion source (HESI) was applied to the analysis. Gradient
chromatographic separation was performed at room temperature on a Luna C8(2) Mercury column
(20 mm × 2.0 mm, particle size 5.0 µm) protected by a C8 guard column (2 × 2 mm) (Phenomenex,
Torrance, CA, USA) by using ammonium formate (15 mM, pH = 3) as Solvent A and acetonitrile as
Solvent B (see Table 4). The calibration curve was shown to be linear over the concentration range of
1–1000 ng/mL.
Table 4. The gradient applied for analysis.
t (min) %B Flow Rate (µL/min)
0 40 250
0.5 40 250
2 70 250
2.1 90 600
2.5 90 600
2.6 40 600
4.0 40 600
4.1 40 250
4.5 40 250
The mass spectrometer was used in a positive mode with the following parameters of the H-ESI
source: spray voltage at 3.5 kV, capillary temperature at 253 ◦C, aux gas heater temperature at 406 ◦C,
sheath gas flow rate at 46 L/h, aux gas flow rate at 11 L/h, sweep gas flow rate at 2 L/h, S-lens RF
level at 50.0 (source auto-defaults). Parallel-reaction-monitoring (PRM) mode was used for quantifying
by monitoring the transitions: m/z 352→ 115 and 352→ 141 for MEL and m/z 332→ 95 and 332→
121 for piroxicam. The normalized collision energies (NCE) for specific quantification were optimized
to maximize sensitivity. The NCE was 24 for MEL and 29 for piroxicam. A valve placed after the
analytical column was programmed to switch flow onto MS only when analytes of interest elute
from the column (brain samples: 0.9–2.1 min; plasma samples: 0.7–2.0 min) to prevent excessive
contamination of the ion source and ion optics. Washing procedures of the autosampler before and
after injecting samples were programmed in order to avoid carry-over of analytes.
Data acquisition and processing were carried out using Xcalibur and Quan Browser (version
4.0.27.19) software (Thermo Fisher Scientific, San Jose, CA, USA).
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Calculations of the Area under the Time-Concentration Curve (AUC) and Statistical Analysis
The area under the curve (AUC) of the time (min)–concentration (ng/mL) curves of each animal
and the statistical analysis were performed with Prism 5.0 software (GraphPad Software Inc., La Jolla,
CA, USA). All reported data are means ± SD. The unpaired t-test was used to determine statistical
significance. Changes were considered statistically significant at p < 0.05. The ratio of AUC value, after
IN application in brain in comparison with the AUC of IV administration (absolute bioavailability for
brain—% abs. BA for brain) was determined according to the formula below.
% abs. BA f or brain =
AUCbrain IN
AUCbrain IV
× 100.
Drug targeting efficiency percentage (%DTE)—relative exposure of the brain to the drug following
IN administration vs. systemic administration—was calculated according to the formula below.
%DTE =
(
AUCbrain
AUCblood
)
IN(
AUCbrain
AUCblood
)
IV
× 100 (1)
The value of %DTE can range from −∞ to ∞, and the values higher than 100% indicate more
efficient drug delivery to the brain following IN administration when compared to the systemic
administration [33].
4. Conclusions
The results confirmed both trans-epithelial and axonal transport of MEL and MELP. Nanonized
MEL showed better absorption and constant plasma concentration of the drug after five minutes
of administration when compared with MELP. It is connected to the high specific surface area,
the enhanced saturation solubility [34], and the high mucoadhesivity of the nano MEL spray [35].
The reduction of the particle size of MEL into the nano range resulted in the increased adhesiveness
to surfaces [30], which ensured the rapid appearance of the drug in the blood plasma. Initial slow
absorption of MELP could be explained with low transepithelial activity of its dissociated form,
which decreased the mucoadhesivity of the spray. Plasma AUC values were similar and significantly
lower in case of the administration of IN forms compared with MEL-containing IV injection. It can be
stated that the “nose-to-blood” pathway is determinative in the transport of MEL. This is consistent
with literary data [20–22] where MEL and ketorolac tromethamine were investigated as pain killers.
Otherwise, the ketorolac tromethamine containing nasal spray was the first on the market for pain relief.
The axonal transport of MEL was assumed when the drug appeared in the brain tissues in the
first five minutes after the application of nasal sprays. In terms of cerebral AUC values, the absolute
bioavailability of nano MEL spray was 100% when compared with the IV injection. This can also
be related to the advantageous properties of the nanonized MEL. The IN administration of MEL
and MELP resulted in higher relative accumulation of the drugs (% DTE) in the brain by the axonal
(“nose-to-brain”) and BBB (“blood-to-brain”) transport when compared with IV administration. It is
also important to consider the axonal transport and the pathway through the BBB. Additionally,
the absorbed amount of MEL is less than 0.001% of the total plasma concentration. Further development
and experiments with a higher dose of drugs are necessary to enhance the directly absorbed amount
of MEL into the brain. Few data points are available on IN application of NSAIDs with the aim of
preventing Alzheimer’s disease. This can be related to their anti-inflammatory effect, which is a new
approach to target the brain with NSAIDs [36,37].
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